urticaria
URTICARIA
Urticaria is characterized by sudden appearance of wheals and/or angioedema.
The intensity of the pruritus varies but may be severe enough to disrupt sleep, work or school.
It is classified acute if the urticaria has been present for <6 weeks and chronic if >6 weeks. A specific cause is more likely to be identified in acute cases.
It can be triggered by immunological or nonimmunological mechanism.
Drug Information

Indication: Prophylactic treatment of bronchial asthma. Symptomatic treatment of allergic rhinitis, dermatitis, urticaria ...

Indication: Relief of symptoms associated w/ allergic rhinitis; symptoms & signs of chronic urticaria & other alle...

Indication: Symptomatic treatment of seasonal rhinitis, perennial allergic rhinitis & urticaria of allergic origin.

Indication: Allegic conditions including hay fever, urticaria, angioedema, vasomotor rhinitis, allergic eczema, atopic &am...

Indication: Active duodenal, benign gastric, stomal & recurrent ulceration, persistent dyspeptic symptoms w/ or w/o ul...

Indication: Allergic conditions including hay fever, urticaria, angioedema, vasomotor rhinitis, allergic eczema, atopic &a...

Indication: Symptomatic relief of allergic rhinitis, chronic urticaria & other dermatological disorder.

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

Indication: Symptomatic relief of allergy or hypersensitivity reactions eg, hay fever, urticaria, angioedema, rhinitis, co...

Became
carbinoxamine maleate + pseudoephedrine hydrochlor...

Indication: Symptomatic relief of seasonal & allergic rhinitis, vasomotor rhinitis.

2  /  16
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.